IP Library Granted Patent US 9,907,853
Granted Patent B2
US 9,907,853 · App. 15/599,532 · Granted Mar 6, 2018

Approach to treatment of hyperglycemia using a nanoparticle encapsulated peptide

Inventor: Mahin D. Maines (Rochester, NY)
Assignee: UNIVERSITY OF ROCHESTER
A61K47/42A61K9/51A61K38/16C07K7/06C07K7/08G01N2800/042
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,907,853
App. No.
15/599,532
Granted
Mar 6, 2018
Kind
B2
Abstract

The present invention relates to compositions and methods for treating or preventing hyperglycemia and diseases associated with hyperglycemia. In certain embodiments, the composition comprises a peptide having the amino acid sequence KRSCYK wherein the peptide consists of D-amino acids is useful in treating or preventing diabetes. In some aspects, the peptide of the invention is encapsulated in a nanoparticle.

Claims (14)

1. An isolated peptide comprising an amino acid sequence of KRSCCYK (SEQ ID NO: 1), wherein each amino acid of the peptide is in D configuration (D-amino acid).

2. The peptide of claim 1 , wherein the peptide further comprises an acetyl group on the N-terminus of the peptide.

3. The peptide of claim 1 , wherein the peptide further comprises an amido group on the C-terminus of the peptide.

4. A composition comprising the peptide of claim 1 , or a pharmaceutically acceptable carrier.

5. The composition of claim 4 is in a form of a nanoparticle.

6. The composition of claim 5 , wherein the nanoparticle comprises a core comprising heparin, protamine, and the peptide.

7. The composition of claim 6 , wherein the weight ratio of protamine to heparin is about 0.3:1 to about 0.6:1.

8. The composition of claim 5 , wherein the nanoparticle comprises a membrane comprising cholesterol and DOTAP.

9. A method for treating diabetes in a subject, the method comprising administering to a subject an effective amount of a peptide of claim 1 .

10. The method of claim 9 , wherein the peptide comprises an acetyl group on the N-terminus of the peptide.

11. The method of claim 9 , wherein the peptide further comprises an amido group on the C-terminus of the peptide.

12. The method of claim 9 further comprising administering a second therapeutic agent.

13. The method of claim 12 , wherein the second therapeutic agent is an anti-diabetic agent.

14. The method of claim 12 , wherein the second therapeutic agent is insulin.

Assignments (2)
CONFIRMATORY LICENSE Recorded Feb 2, 2018
From: UNIVERSITY OF ROCHESTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045242/0600 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2017
From: MAINES, MAHIN D.
To: UNIVERSITY OF ROCHESTER
Reel/Frame 044604/0154 →
Continuity (2)
Provisional Application 62339314 · May 20, 2016
Related Publication 20170333564A1 · Nov 23, 2017